Medicare Part B premiums expected to rise almost 10% in 2026

CMS cuts deal on four oncology drugs under Medicare

The Center for Medicare and Medicaid Services said it has negotiated down the price of 15 drugs, including significant discounts to four costly cancer treatment drugs, according to an announcement from Nov. 25.

Hospitals sue to block CMS 340B drug rebate pilot

The American Hospital Association, joined by four community-based hospitals, has sued HHS over a pilot program to reimburse drug costs to safety net hospitals enrolled in the 340B program through a rebate—a departure of the status quo of up-front discounts.

Trump signs CR that funds government through Jan. 30, ending the longest shutdown in U.S. history

On the evening of Nov. 12, President Donald Trump signed a continuing resolution that officially ended the 43-day-long U.S. government shutdown that began on Oct. 1.

CMS announces GENEROUS drug payment model aimed at lowering Medicaid drug prices

CMS announced a new drug payment model called the GENErating cost Reductions for U.S. Medicaid (GENEROUS) Model that the agency plans to pilot next year.

November 14, 2025

Vol.51 No.42

By Sara Willa Ernst and Jacquelyn Cobb

Cancer Policy

White House makes deal with Eli Lilly, Novo Nordisk to lower weight loss drug prices and begin Medicare coverage

The White House Nov. 6 announced a deal with drugmakers Eli Lilly and Co. and Novo Nordisk to expand coverage and reduce prices for their obesity treatments, Zepbound and Wegovy.

Insurance premiums set to skyrocket if Congress doesn’t reach a deal

With the start of open enrollment less than one week away, millions of Americans are getting their first look at the sharp increases many will pay next year if Congress fails to extend the enhanced premium tax credits that have expanded healthcare access to over 13 million people since 2021.

October 24, 2025

Vol.51 No.39

By Claire Marie Porter